Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879078 | 1.00 | POLB (0.34) | POLBTRPM8LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6879189 | 0.90 | NPSR1 (0.36) | TRPM8ALDH1A1L3MBTL1MAPT | |
| SCHEMBL6077512 | 0.89 | ALDH1A1 (0.38) | LMNASMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL6078978 | 0.89 | BCL2A1 (0.37) | POLBLMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6077491 | 0.89 | ALDH1A1 (0.44) | TRPM8SMN1; SMN2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL6077514 | 0.89 | ALDH1A1 (0.38) | LMNASMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL6877621 | 0.89 | ALDH1A1 (0.44) | TRPM8SMN1; SMN2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL6078972 | 0.89 | BCL2A1 (0.37) | POLBLMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6450808 | 0.88 | TAS2R14 (0.37) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL6077839 | 0.87 | LOXL2 (0.38) | POLBLMNASMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | POLB 23/4885TRPM8 4807/4885LMNA 3521/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | POLB 64/4885TRPM8 4119/4885LMNA 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.